$140M Series B financing led by Casdin Capital and GV (formerly Google Ventures) with participation from leading global life science investors
Proceeds accelerate development of products against a broad range of respiratory viruses through mucosal protection
Supported by world class team experienced in breakthrough innovations for infectious diseases
AMSTERDAM and BOSTON - January 25, 2022 - Leyden Laboratories B.V. today announced closing a $140M Series B financing, bringing its total capital raised to approximately $200M in 2021. Series A investors Casdin Capital and GV (formerly Google Ventures) led the round that included incoming investors SoftBank Vision Fund 2, Invus, and Bluebird Ventures, and existing Series A investors F-Prime Capital and Byers Capital/Brook Byers.
The Board will expand to include Eli Casdin of Casdin Capital as a new member. Vali Barsan of Softbank Investment Advisers, Jeff Bird of Bluebird Ventures, and Suzanne Jung Angell of Casdin Capital join the Board as observers.
Leyden Labs has a pipeline of mucosal protection products, including PanFlu which uses CR9114, the only human monoclonal influenza antibody that protects against influenza A and B, in-licensed from Janssen Pharmaceuticals.
"This fundraising underscores our investors' belief that Leyden Labs' platform can generate cornerstone products to combat respiratory diseases," said Koenraad Wiedhaup, a founder and CEO of Leyden Labs.
Eli Casdin, Chief Investment Officer and Founder at Casdin Capital, stated, "Our approach is to uncover the best technologies and enable high-quality management teams to solve some of the world's biggest problems and Leyden Labs is a clear fit."
Leyden Labs consists of a world-class, seasoned team with decades of experience in research, development, manufacturing, and product launches in infectious diseases. Industry veterans from Crucell and Leyden Labs' founders, Jaap Goudsmit (CSO), Ronald Brus (CBO) and Dinko Valerio (Chair of Supervisory Board) are teaming up with executives and scientific leaders from biotech powerhouses like VIR, Harvard and MIT.
David Schenkein, General Partner from GV (formerly Google Ventures) added, "Leyden Labs is led by a highly accomplished team of world-class scientists and experienced product development leaders."
About Pan-influenza (PanFlu)
Leyden Lab's PanFlu intranasal spray is in development to provide prophylactic protection against influenza A and B, offering broad protection against seasonal epidemics and potential future pandemics.
About Leyden Laboratories B.V.
The Company, founded in June 2020, has built an energetic team of world-renowned biotechnology veterans and fresh talent and is backed with $200M by blue chip investors. To learn more, visit www.leydenlabs.com.
Corporate Contact: Leyden Laboratories B.V., investors@leydenlabs.com
Media Contact: Elizabeth Miller, M.D., LifeSci Communications, media@leydenlabs.com
